Tazarotene/ulobetasol - Ortho Dermatologics

Drug Profile

Tazarotene/ulobetasol - Ortho Dermatologics

Alternative Names: Halobetasol propionate/tazarotene; IDP-118; Tazarotene/halobetasol propionate; Ulobetasol/tazarotene

Latest Information Update: 11 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dow Pharmaceutical Sciences
  • Developer Ortho Dermatologics
  • Class Antipsoriatics; Corticosteroids; Cyclopentanes; Keratolytics; Nicotinic-acids; Phenanthrenes; Pyridines; Retinoids; Small molecules
  • Mechanism of Action Retinoid X receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Plaque psoriasis

Most Recent Events

  • 02 Nov 2017 FDA assigns PDUFA action date of 18/06/2018 for tazarotene/ulobetasol for Plaque psoriasis
  • 02 Nov 2017 US FDA accepts NDA for tazarotene/ulobetasol for Plaque psoriasis for review
  • 05 Sep 2017 Preregistration for Plaque psoriasis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top